Moderna is pioneering an entirely new drug modality using messenger RNA therapeutics™ to produce, in vivo, human proteins or antibodies inside patient cells that are in turn active intracellularly or secreted into the serum. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. Moderna has developed a broad intellectual property estate including 125 patent filings with 6,500 claims ranging from novel nucleotide chemistries to specific drug compositions. The company plans to develop and commercialize its innovative mRNA drugs initially for rare diseases and oncology while partnering drug candidates in other therapeutics areas in order to rapidly maximize patient impact. Moderna was founded in 2010 by Flagship VentureLabs™ in association with leading scientists from Harvard University and Massachusetts Institute of Technology.
Noubar Afeyan is Chairman.